Study type: In vitro · Status: Verified against declared source
Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites.
PloS one · 2016
Study scale: Fungal infections, especially those caused by antibiotic resistant pathogens, have become a serious public health problem due to the growing number of immunocompromised patients, including those subjected to anticancer treatment or suffering from HIV infection.
Abstract only: Open source record
Product or molecular entity relationships
- LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
In the present study, we aimed to assess the candidacidal activity of three ceragenins—CSA-13, CSA-131 and CSA-192 in comparison to LL-37 and omiganan against several strains of Candida in an experimental setting containing extracellular DNA (eDNA) as a factor promoting biofilm formation.
Methods
In the present study, we aimed to assess the candidacidal activity of three ceragenins—CSA-13, CSA-131 and CSA-192 in comparison to LL-37 and omiganan against several strains of Candida in an experimental setting containing extracellular DNA (eDNA) as a factor promoting biofilm formation.
Scale or participants
Fungal infections, especially those caused by antibiotic resistant pathogens, have become a serious public health problem due to the growing number of immunocompromised patients, including those subjected to anticancer treatment or suffering from HIV infection.
Key findings
Fungal infections, especially those caused by antibiotic resistant pathogens, have become a serious public health problem due to the growing number of immunocompromised patients, including those subjected to anticancer treatment or suffering from HIV infection.
Limitations and uncertainty
Fungal infections, especially those caused by antibiotic resistant pathogens, have become a serious public health problem due to the growing number of immunocompromised patients, including those subjected to anticancer treatment or suffering from HIV infection.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.